Pacira Pharma (PCRX) Misses Q3 EPS by 83c

Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of ($0.02), $0.83 worse than the analyst estimate of $0.81. Revenue for the quarter came in at $167.5 million versus the consensus estimate of $171.24 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Unifi, Inc. (UFI) Misses Q4 EPS by 11c
• Lowe's slashes full-year sales outlook amid DIY spending pressure